TPCW
IBB icon

TD Private Client Wealth’s iShares Biotechnology ETF IBB Stock Holding History

TD Private Client Wealth’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.36M Buy
12,383
+11,333
+1,079% +$1.95M 0.04% 238
2026
Q1 		$177K Sell
1,050
-16,175
-94% -$2.77M ﹤0.01% 674
2025
Q4 		$2.91M Buy
17,225
+10,717
+165% +$1.74M 0.06% 198
2025
Q3 		$940K Sell
6,508
-1,084
-14% -$148K 0.02% 376
2025
Q2 		$960K Buy
7,592
+4,636
+157% +$569K 0.02% 373
2025
Q1 		$378K Buy
2,956
+210
+8% +$28.5K 0.01% 491
2024
Q4 		$363K Buy
2,746
+81
+3% +$11.4K 0.01% 499
2024
Q3 		$388K Sell
2,665
-22
-0.8% -$3.18K 0.01% 485
2024
Q2 		$369K Sell
2,687
-321
-11% -$42.9K 0.01% 479
2024
Q1 		$413K Sell
3,008
-494
-14% -$67.5K 0.01% 472
2023
Q4 		$476K Sell
3,502
-1,028
-23% -$125K 0.02% 444
2023
Q3 		$554K Sell
4,530
-221
-5% -$28.1K 0.02% 397
2023
Q2 		$603K Sell
4,751
-114
-2% -$14.8K 0.03% 414
2023
Q1 		$628K Sell
4,865
-157
-3% -$20.6K 0.03% 400
2022
Q4 		$659K Sell
5,022
-119
-2% -$15.4K 0.03% 384
2022
Q3 		$601K Buy
5,141
+100
+2% +$12.4K 0.03% 383
2022
Q2 		$593K Sell
5,041
-311
-6% -$36.9K 0.03% 388
2022
Q1 		$697K Sell
5,352
-8,644
-62% -$1.13M 0.03% 387
2021
Q4 		$2.14M Buy
13,996
+317
+2% +$49.1K 0.09% 225
2021
Q3 		$2.21M Sell
13,679
-1,646
-11% -$277K 0.09% 216
2021
Q2 		$2.51M Buy
15,325
+146
+1% +$22.5K 0.11% 200
2021
Q1 		$2.29M Buy
15,179
+6,013
+66% +$955K 0.11% 204
2020
Q4 		$1.39M Buy
9,166
+5,383
+142% +$769K 0.07% 268
2020
Q3 		$512K Buy
+3,783
New +$513K 0.03% 354

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

TD Private Client Wealth's IBB Position: Q2 2026 in Review

TD Private Client Wealth increased its iShares Biotechnology ETF (IBB) stake by 1,079% in Q2 2026, buying an estimated $1.95M and bringing the position to 12,383 shares worth $2.36M. The position accounts for 0.04% of the portfolio, ranked #238.

TD Private Client Wealth first reported a position in IBB in Q3 2020 and has held it in 24 quarters since. The position peaked at $2.91M in Q4 2025. 954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • TD Private Client Wealth held 12,383 shares of iShares Biotechnology ETF worth $2.36M as of Q2 2026.
  • TD Private Client Wealth bought 11,333 iShares Biotechnology ETF shares in Q2 2026, an estimated $1.95M.
  • iShares Biotechnology ETF made up 0.04% of TD Private Client Wealth's portfolio in Q2 2026, its #238 holding.
  • TD Private Client Wealth first reported a position in iShares Biotechnology ETF in Q3 2020 and has held it in 24 quarters since.
  • TD Private Client Wealth's iShares Biotechnology ETF position peaked at $2.91M in Q4 2025.
  • 954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.